Denton John Russel sold $239K of CAI

Denton John Russel (See Remarks) sold 7,500 shares of Caris Life Sciences, Inc. (CAI) at $31.82 ($0.24M total) on 2026-09-22.

Original reporting
SEC EDGAR · Denton John Russel
Published Sep 23, 2026, 9:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 23, 2026, 9:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CAI
Neutral
high confidence
Mentioned
$CAI
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CAINeutralLow
01

Why it matters

The transaction is routine and unlikely to move the stock.

02

Market read

Minor insider sale with limited market relevance.

03

What to watch

Potential tax-driven liquidity event; no operational implications.

Relevance 4/10Novelty 4/10Timing: post-market 2026-09-22

Background

Form 4 disclosures provide the first public record of insider transactions.

Company-level read

Ticker impact

$CAINeutralHigh confidence
Context

Officer Denton John Russel sold 7,500 shares for $238,626 in a Form 4 filing.

Expected impact

No significant move expected.

Evidence & confidence

Sale size is modest relative to total holdings and market cap; typical for routine diversification.

Market effects

None; the sale does not affect the broader biotech sector.

None; limited to the company.

None.

Counterpoint

Even small insider sales can signal concerns; monitor future filings for pattern.

Key entities

  • Caris Life Sciences, Inc.

    Biotech firm focused on cancer diagnostics.

  • Denton John Russel

    Company officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CAIMed

Caris Life Sciences Inc (CAI) Q3 2026 Earnings Call Highlights: Record Revenue, Sixth

Caris Life Sciences (CAI) reported Q3 2026 revenue growth, but faced negative free cash flow of $39.7M due to capital expenditures. Operating expenses rose $48.1M year-over-year, and full-year GAAP opex guidance was raised to ~$620M. New product launches without reimbursement may pressure margins. Q4 pharma R&D services revenue is expected to decline sequentially. The company is expanding its commercial team and expects positive free cash flow in Q4.

$CAIHigh

Caris Life (CAI) Q3 2026 Earnings Call Transcript

Caris Life (CAI) reported Q3 2026 earnings, highlighting 21% year-over-year clinical case growth and 27% revenue increase to $275M. The company launched new products, including Caris Assure for monitoring and plans to launch Caris Confirm for MRD in December. Caris Detect, their early-stage cancer detection test, is gaining market traction. The company maintained profitability with adjusted EBITDA of $44.4M and net income of $15.3M.

$CAIMed

TD Cowen raises Caris Life Sciences stock price target on pipeline

TD Cowen raised its price target for Caris Life Sciences (CAI) to $38 from $36, maintaining a Buy rating. The company reported Q3 sales beating expectations by 9%, with revenue up 85% year-over-year and a 70% gross margin. Despite this, shares fell 15% post-market due to an earnings miss. The stock has gained 65% since pre-Q2 levels, but InvestingPro suggests it may be overvalued.